Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ovarian Cancer Detection by Uterine Lavage DNA and Serum Proteins: a Phase 2 Biomarker Study

NCT04794322 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04794322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04794322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ovarian Cancer Detection by Uterine Lavage DNA and Serum Proteins: a Phase 2 Biomarker Study
Lead sponsor
Massachusetts General Hospital
Phase
Observational
Overall status
Recruiting
Start date
April 13, 2020
Completion date
August 31, 2028
Enrollment
250 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube neoplasms, high grade ovarian serous adenocarcinoma, ovarian epithelial carcinoma, ovarian neoplasms, stage i ovarian cancer, stage ii ovarian cancer, stage iii ovarian cancer ajcc v8, stage iiia ovarian cancer ajcc v8, stage iiia1 ovarian cancer ajcc v8, stage iiia2 ovarian cancer ajcc v8, stage iiib ovarian cancer ajcc v8, stage iiic ovarian cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iva ovarian cancer ajcc v8, stage ivb ovarian cancer ajcc v8